The National Kidney Foundation is celebrating a victory today after the FDA published (.pdf) a proposal to make it easier to identify biologic drugs by adding a four-letter suffix to the non-proprietary (generic) name. Making a “generic” version (biosimilar) of a biologic drug is more complex than a typical generic drug. What does this mean for patients? Even small changes in the manufacturing process can potentially lead to side effects in some patients not found with the original biologic drug. It is therefore important to patient safety to make sure that clinicians, pharmacists and patients can easily determine which biosimilar is being used. The assigning of a unique name to each biosimilar will aide in this awareness. Continue reading
In a recent New York Times Opinionator piece, “Fixes: It’s Time to Compensate Kidney Donors” (August 7), the author encourages compensation and incentives for kidney donors. The National Kidney Foundation (NKF) firmly believes that paying for organs isn’t the answer since there are effective, proven methods to increase donation that are currently underutilized.
NKF supports increasing the availability of organs and believes kidney transplantation is the most cost effective treatment in the long term. Accordingly, NKF has worked with Congress consistently for many years to address extending Medicare immunosuppressant transplant medications to cover the life of the transplant.
NKF’s Chief Medical Officer speaks at a briefing with Congressional staff members on Capitol Hill
“Kidney disease is not dialysis; dialysis is a treatment for kidney failure,” said Dr. Joseph Vassalotti, the National Kidney Foundation’s (NKF) Chief Medical Officer, at a briefing with Congressional staff members on Capitol Hill earlier this week.
Dr. Vassalotti’s comments come at a time when lawmakers on the Hill and policymakers at Centers for Medicare & Medicaid Services (CMS) are focused on treatment and payment for end-stage kidney disease care in the United States.
By Troy Zimmerman, Vice President, Government Relations, NKF
The members of NKF’s Kidney Action Committee (KAC) were eager to roll up their sleeves and get going in their new roles. First up, our liaisons were asked to draft letters to the editors of their local papers to raise awareness about the need for increased research funding for kidney disease. Our goal was to highlight the importance of investing in research and programs to improve early detection of kidney disease, slow progression and improve access to kidney transplantation. This is a cost-effective strategy with the power to save lives, kidneys and money. Continue reading
We’re pleased to announce that the 21stCentury Cures Bill has passed in the House of Representatives with a 344-77 vote. The bill guarantees increased NIH funding over five years and will ensure greater investment in research, including research on kidney disease.
Here are some of the key provisions that were included in the 21st Century Cures Bill: Continue reading
By Troy Zimmerman, Vice President, Government Relations, NKF
Call your U.S. Representatives and ask them to vote yes on H.R. 6, the 21st Century Cures Act. While no provisions specific to kidney disease are included in the 21st Century Cures legislation, this bill sets the stage for addressing barriers to develop treatments and potential cures for diseases where therapies are currently limited – such as they are for kidney disease. The bill also increases research funding for the National Institutes for Health (NIH), where important research for kidney disease is conducted and funded under the National Institutes for Diabetes and Digestive and Kidney Diseases (NIDDK).
Not many people know that healthy kidneys and healthy hearts are intrinsically linked. In fact, a recent study conducted by Johns Hopkins University and funded by the National Kidney Foundation found that kidney function can be a better predictor of heart attacks and strokes than standard cholesterol and blood pressure tests.
This is yet another reason why we need greater awareness of chronic kidney disease (CKD) and a concerted effort by primary care practitioners to test for CKD among those at highest risk – including individuals with diabetes, hypertension, age over 60, and a family history of kidney failure.
Because the kidney-heart connection is so important to overall health, the National Kidney Foundation has partnered with the Million Hearts Initiative – a coalition of groups and individuals working to prevent 1 million heart attacks and strokes by 2017. We encourage you to read NKF’s commitment to the Million Hearts Initiative.
You can also help us save kidneys, hearts, and lives. Raise awareness among the general public about the importance of our kidneys by sharing our EverybodyPees campaign with your social media network. This campaign highlights the important role of urine screening to keep kidneys, and hearts, healthy. You can also sign up for our Advocacy Action Center to be alerted to opportunities to let your Members of Congress know how they can help drive greater prevention of kidney disease, which will also help us reduce heart attacks and strokes for years to come.
By Kerry Willis, PhD, NKF Chief Scientific Officer
Over 450,000 Americans with kidney failure depend on dialysis to stay alive, and since 1999 survival rates have continued to increase among this highly vulnerable population, as summarized in the United States Renal Data System 2014 Annual Data Report (USRDS 2014 ADR).[i] This is a significant achievement made possible through the ongoing collaborative efforts of healthcare professionals, academics and the National Kidney Foundation (NKF), who work together to make improvements in the care of individuals living with kidney failure.
The National Kidney Foundation (NKF) has launched a new patient advocacy and engagement program to expand its grassroots network at the state level.
The Kidney Action Committee is comprised of 60 patient liaisons, including one from each state, who are personally affected by kidney disease. These individuals will use their experience to advise government agencies, research organizations, and policy and health organizations on kidney disease. They will also provide input on the development of NKF public policy positions and the implementation of kidney disease education programs.
The National Kidney Foundation (NKF) is pleased with the Senate Finance Committee’s announcement, under the leadership of Chairman Orrin Hatch (R-Utah) and Ranking Member Ron Wyden (D-Ore.), to lower healthcare costs and improve care for individuals with multiple chronic illnesses.
According to the committee, the vast majority of Medicare dollars are spent caring for patients living with multiple persistent, chronic health conditions like chronic kidney disease (CKD). The variety of services required for this care can often be uncoordinated and costly.